Literature DB >> 26994576

Activation of the transcription factor EB rescues lysosomal abnormalities in cystinotic kidney cells.

Laura R Rega1, Elena Polishchuk2, Sandro Montefusco2, Gennaro Napolitano2, Giulia Tozzi3, Jinzhong Zhang4, Francesco Bellomo5, Anna Taranta5, Anna Pastore6, Roman Polishchuk2, Fiorella Piemonte3, Diego L Medina2, Sergio D Catz4, Andrea Ballabio2, Francesco Emma5.   

Abstract

Nephropathic cystinosis is a rare autosomal recessive lysosomal storage disease characterized by accumulation of cystine into lysosomes secondary to mutations in the cystine lysosomal transporter, cystinosin. The defect initially causes proximal tubular dysfunction (Fanconi syndrome) which in time progresses to end-stage renal disease. Cystinotic patients treated with the cystine-depleting agent, cysteamine, have improved life expectancy, delayed progression to chronic renal failure, but persistence of Fanconi syndrome. Here, we have investigated the role of the transcription factor EB (TFEB), a master regulator of the autophagy-lysosomal pathway, in conditionally immortalized proximal tubular epithelial cells derived from the urine of a healthy volunteer or a cystinotic patient. Lack of cystinosin reduced TFEB expression and induced TFEB nuclear translocation. Stimulation of endogenous TFEB activity by genistein, or overexpression of exogenous TFEB lowered cystine levels within 24 hours in cystinotic cells. Overexpression of TFEB also stimulated delayed endocytic cargo processing within 24 hours. Rescue of other abnormalities of the lysosomal compartment was observed but required prolonged expression of TFEB. These abnormalities could not be corrected with cysteamine. Thus, these data show that the consequences of cystinosin deficiency are not restricted to cystine accumulation and support the role of TFEB as a therapeutic target for the treatment of lysosomal storage diseases, in particular of cystinosis.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cystinosis; pediatric nephrology; proximal tubule; renal pathology

Mesh:

Substances:

Year:  2016        PMID: 26994576     DOI: 10.1016/j.kint.2015.12.045

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  45 in total

1.  First Successful Conception Induced by a Male Cystinosis Patient.

Authors:  Koenraad R Veys; Kathleen W D'Hauwers; Angelique J C M van Dongen; Mirian C Janssen; Martine T P Besouw; Ellen Goossens; Lambert P van den Heuvel; Alex A M M Wetzels; Elena N Levtchenko
Journal:  JIMD Rep       Date:  2017-04-13

Review 2.  Regulation of TFEB activity and its potential as a therapeutic target against kidney diseases.

Authors:  Weihuang Zhang; Xiaoyu Li; Shujun Wang; Yanse Chen; Huafeng Liu
Journal:  Cell Death Discov       Date:  2020-05-01

3.  Interaction between galectin-3 and cystinosin uncovers a pathogenic role of inflammation in kidney involvement of cystinosis.

Authors:  Tatiana Lobry; Roy Miller; Nathalie Nevo; Celine J Rocca; Jinzhong Zhang; Sergio D Catz; Fiona Moore; Lucie Thomas; Daniel Pouly; Anne Bailleux; Ida Chiara Guerrera; Marie-Claire Gubler; Wai W Cheung; Robert H Mak; Tristan Montier; Corinne Antignac; Stephanie Cherqui
Journal:  Kidney Int       Date:  2019-03-06       Impact factor: 10.612

4.  Cross-regulation of defective endolysosome trafficking and enhanced autophagy through TFEB in UNC13D deficiency.

Authors:  Jinzhong Zhang; Jing He; Jennifer L Johnson; Gennaro Napolitano; Mahalakshmi Ramadass; Farhana Rahman; Sergio D Catz
Journal:  Autophagy       Date:  2019-04-05       Impact factor: 16.016

Review 5.  Small molecules as therapeutic agents for inborn errors of metabolism.

Authors:  Leslie Matalonga; Laura Gort; Antonia Ribes
Journal:  J Inherit Metab Dis       Date:  2016-12-13       Impact factor: 4.982

Review 6.  The complex relationship between TFEB transcription factor phosphorylation and subcellular localization.

Authors:  Rosa Puertollano; Shawn M Ferguson; James Brugarolas; Andrea Ballabio
Journal:  EMBO J       Date:  2018-05-15       Impact factor: 11.598

7.  The aminoglycoside geneticin permits translational readthrough of the CTNS W138X nonsense mutation in fibroblasts from patients with nephropathic cystinosis.

Authors:  Emma J Brasell; LeeLee Chu; Reyhan El Kares; Jung Hwa Seo; Robin Loesch; Diana M Iglesias; Paul Goodyer
Journal:  Pediatr Nephrol       Date:  2018-11-09       Impact factor: 3.714

8.  Cell-Based Phenotypic Drug Screening Identifies Luteolin as Candidate Therapeutic for Nephropathic Cystinosis.

Authors:  Ester De Leo; Mohamed A Elmonem; Sante Princiero Berlingerio; Marine Berquez; Beatrice Paola Festa; Roberto Raso; Francesco Bellomo; Tobias Starborg; Manoe Jacoba Janssen; Zeinab Abbaszadeh; Sara Cairoli; Bianca Maria Goffredo; Rosalinde Masereeuw; Olivier Devuyst; Martin Lowe; Elena Levtchenko; Alessandro Luciani; Francesco Emma; Laura Rita Rega
Journal:  J Am Soc Nephrol       Date:  2020-06-05       Impact factor: 10.121

9.  Cystinosin, the small GTPase Rab11, and the Rab7 effector RILP regulate intracellular trafficking of the chaperone-mediated autophagy receptor LAMP2A.

Authors:  Jinzhong Zhang; Jennifer L Johnson; Jing He; Gennaro Napolitano; Mahalakshmi Ramadass; Celine Rocca; William B Kiosses; Cecilia Bucci; Qisheng Xin; Evripidis Gavathiotis; Ana María Cuervo; Stephanie Cherqui; Sergio D Catz
Journal:  J Biol Chem       Date:  2017-05-02       Impact factor: 5.157

10.  Use of Human Induced Pluripotent Stem Cells and Kidney Organoids To Develop a Cysteamine/mTOR Inhibition Combination Therapy for Cystinosis.

Authors:  Jennifer A Hollywood; Aneta Przepiorski; Randall F D'Souza; Sreevalsan Sreebhavan; Ernst J Wolvetang; Patrick T Harrison; Alan J Davidson; Teresa M Holm
Journal:  J Am Soc Nephrol       Date:  2020-03-20       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.